Printer Friendly

Aastrom Biosciences receives orphan product designation from FDA for bone marrow stem cell product.

Aastrom Biosciences, Inc., Ann Arbor, MI announced the FDA has granted orphan product status to the company's SC-1 autologous bone marrow stem cells using its AastromReplicell System. The company says its therapeutic ex vivo-produced bone marrow stem cells received the designation for use in cancer patients requiring a stem cell transplant following high-dose chemotherapy, but who are unable to obtain sufficient numbers of blood stem cells for adequate treatment using current transplant methods.

The FDA awards orphan product classification to new approaches that may offer therapeutic value for the treatment of rare diseases and conditions. Products receiving the designation may be entitled to entitled to expedited FDA review. In addition the company would be entitled to marketing exclusivity for 7 years should the product ultimately receive FDA approval.

Contact: Glenn Silver - (212) 845-4259, Web site - www.aastrom.com.
COPYRIGHT 2002 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Aastrom Biosciences receives orphan product designation from FDA for bone marrow stem cell product.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 27, 2002
Words:138
Previous Article:Lifebank Cryogenics seeking to become first publicly traded stem cell bank in Canada.
Next Article:Commentary - Infighting between tissue banks, fueled by faulty media reports, impacting peoples' decision to donate.
Topics:


Related Articles
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom Biosciences launches AastromReplicell in Europe for use in stem cell therapy.
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Aastrom Biosciences patents cassette approach to growing human cells.
Aastrom receives patent covering integrated system for producing human cells.
AnorMED receives orphan drug designation new agent in stem cell transplants for cancer patients.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.
Aastrom receives patent expanding coverage for its single-pass perfusion technology.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |